Memantine Hydrochloride Pinewood

Memantine Hydrochloride, the active ingredient in Memantine Hydrochloride Pinewood, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantine Hydrochloride Pinewood as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is indicated for the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

- Alzheimer’s disease: improves cognition, daily functioning, and slows disease progression in moderate to severe stages.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Hypertension: elevated blood pressure readings. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, pruritus, or angioedema. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Cardiac arrhythmia: irregular heart rhythm. - Suicidal thoughts: emergence of depressive ideation.

Memantine Hydrochloride requires careful assessment before use. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests regularly. - History of seizures: evaluate risk versus benefit, as the drug can lower seizure threshold. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion in milk; consider alternatives. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Memantine Hydrochloride can interact with several medication classes.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine, ketamine): may increase neurotoxicity. - Strong CYP450 inducers (e.g., carbamazepine, phenytoin): may reduce memantine plasma levels. - Concomitant use with high‑dose anticholinergics: may exacerbate cognitive side effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood pressure lowering effect. - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Anticholinergic agents: monitor for worsening confusion. - Diuretics: watch for electrolyte disturbances.